Morgan Stanley cuts Coupang stock price target on margin outlook By Investing.com

Morgan Stanley cut Coupang’s price target to $28 from $29 while keeping an Overweight rating, citing near-term margin pressure despite improving revenue trends. Management guided Q2 2026 revenue growth of 8% to 10% but adjusted EBITDA margins of just 1% to 2%, down 300 to 400 bps year over year, and Morgan Stanley trimmed 2026/2027 EBITDA estimates by 2% and 14%. Coupang also posted Q1 2026 EPS of -$0.15 versus -$0.03 expected, although revenue slightly beat at $8.5B vs. $8.49B.

Analysis

The market is likely misreading this as a simple post-incident recovery story; it is really a margin deferral story. If management is reinvesting before revenue fully normalizes, the near-term optics will stay weak even as unit economics improve, which usually caps multiple expansion until investors see a clean inflection in contribution margin and fixed-cost leverage. That makes the next two quarters more about evidence quality than headline growth rate.

Second-order, the competitive implication is that smaller Korean/Asian commerce peers may not be able to match the same pace of customer re-acquisition if they lack the scale to absorb elevated fulfillment and sourcing costs. If the “lost members” have already reactivated, the remaining question is not demand recovery but retention quality and promo intensity; if the company has to buy back frequency, gross margin recovery could lag well into 2H26. Any regulatory fine is a separate overhang, but the larger risk is that it forces management to prioritize reputational repair over operating discipline.

The contrarian setup is that consensus appears to be anchoring on valuation support while underestimating the duration of the earnings reset. At ~187x P/E, the stock does not need a bad quarter to underperform; it only needs the market to believe that operating leverage is six months further out than planned. That said, if monthly trends continue improving, the stock can re-rate quickly because crowded skepticism leaves room for a sharp squeeze on even modest margin stabilization.

Best risk/reward is to trade the path, not the destination: the upside case is a 2H26 re-rating, while the downside is another 2-3 quarters of range-bound drift. The asymmetry favors using options or pairs rather than outright directional equity until the company prints a quarter with both revenue acceleration and margin containment.

Key Decisions for Investors

• Keep CPNG on a tactical underweight/avoid list into the next earnings cycle; the setup favors sideways-to-down action for the next 1-2 quarters unless gross margin and EBITDA margin inflect together.
• For longs with conviction in the recovery, express it via a call spread on CPNG 3-6 months out rather than stock; you want exposure to a 2H26 re-rating without paying full multiple risk upfront.
• Pair trade idea: long a higher-quality consumer platform with clearer operating leverage versus short CPNG to isolate execution risk from sector beta; this works best over the next 1-2 quarters while the valuation gap remains wide.
• If the stock sells off on the next regulatory headline without a change in customer metrics, consider buying the dip only on a staged basis; the downside catalyst is likely event-driven, while the upside catalyst is operational and slower.
• Use $20 as a near-term technical risk line and the next earnings print as the key catalyst window; a decisive beat on both revenue and margin guidance would justify closing any bearish stance quickly.